Compare XPER & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | CNTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | 1460 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 283.9M |
| IPO Year | 2021 | 2021 |
| Metric | XPER | CNTX |
|---|---|---|
| Price | $5.48 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $11.00 | $6.60 |
| AVG Volume (30 Days) | 367.9K | ★ 937.4K |
| Earning Date | 05-06-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,105,000.00 | N/A |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.07 | $0.49 |
| 52 Week High | $8.24 | $3.62 |
| Indicator | XPER | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 47.55 |
| Support Level | $5.07 | $2.07 |
| Resistance Level | $6.37 | $2.72 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 4.41 | 11.50 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.